Dyax Corp. (NASDAQ: DYAX) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock, offered at a price to the public of $6.50 per share. The gross proceeds to Dyax from this offering are expected to be $60 million, before deducting the underwriting discount and other estimated offering expenses payable by Dyax. The offering is expected to close on or about October 15, 2013, subject to customary closing conditions. Jefferies LLC is acting as the sole book-running manager with Cowen and Company, LLC, Leerink Swann LLC and Needham & Company, LLC acting as the co-managers for the offering. Dyax has granted the underwriters a 30-day option to purchase up to an aggregate of 1,384,615 additional shares of common stock. Dyax intends to use the net proceeds from this offering to fund research and development activities, including the development of DX-2930, a therapeutic candidate for the prophylactic treatment of hereditary angioedema (HAE), and for general corporate purposes. A registration statement relating to the shares of Dyax common stock being offered has been filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and related prospectus, when available, may be obtained from Jefferies LLC, Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About DyaxDyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR ® (ecallantide) business, DX-2930 and the Licensing and Funded Research Program (LFRP). For additional information about Dyax, please visit www.dyax.com. For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com. Disclaimer This press release contains forward-looking statements, including statements regarding the completion of Dyax’s proposed sale of common stock and the use of proceeds from that sale, that involve a number of risks and uncertainties. Statements that are not historical facts are based on Dyax’s current expectations, beliefs and assumptions regarding the market for its common stock. There can be no assurance regarding the completion, timing or size of the proposed offering. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed public offering and others described in Dyax’s most recent Annual Report on Form 10-K for the year ended December 31, 2012. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law. Dyax, the Dyax logo and KALBITOR are registered marks of Dyax Corp.